Evidence map›Paper›PMID 26554440›Full record

ArticlePharmacogenomics2015

AMPD1 polymorphism and response to regadenoson.

Rayan Saab, Aline N Zouk, Ronald Mastouri, Todd C Skaar, Santosh Philips, Rolf P Kreutz

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Vasodilator stress agents for myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rayan SaabDepartment of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1800 N. Capitol Ave, MPC2, ME-400, Indianapolis, IN 46202, USA.
Aline N ZoukDepartment of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1800 N. Capitol Ave, MPC2, ME-400, Indianapolis, IN 46202, USA.
Ronald MastouriDepartment of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1800 N. Capitol Ave, MPC2, ME-400, Indianapolis, IN 46202, USA.
Todd C SkaarDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Clinical Pharmacology Research Institute (R2), Room 402, 950 West Walnut Street, Indianapolis, IN 46202, USA.
Santosh PhilipsDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Clinical Pharmacology Research Institute (R2), Room 402, 950 West Walnut Street, Indianapolis, IN 46202, USA.
Rolf P KreutzDepartment of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, 1800 N. Capitol Ave, MPC2, ME-400, Indianapolis, IN 46202, USA.
Indiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT: NEUROLOGICAL DISORDERS:ALZ, PDC06RR020128 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FIFE, ROSE S · 2004 to 2004
$3.7M
NCATS NIH HHS UL1 TR001108NCATS NIH HHS UL1TR001108NCI NIH HHS CO6-RR020128-01NCRR NIH HHS C06 RR020128NCRR NIH HHS U54-RR025761NCRR NIH HHS UL1 RR025761
6 · The paper itself

Abstract

aimsAMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS &

methodsGenotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing.

resultsCarriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir: -3 ± 15 vs -7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04).

conclusionAMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.

Indexed as

Adenosine A2 Receptor AgonistsAMP DeaminaseBlood PressureExercise TestFemaleHeart RateHumansMaleMiddle AgedPolymorphism, GeneticPurinesPyrazolesAdenosine A2 Receptor AgonistsAMPD1 protein, humanAMP DeaminasePurinesPyrazolesregadenosonadenosinegeneticmyocardial perfusion imagingregadenoson

Identifiers

PMID26554440
PMCPMC4826562
OpenAlexW2157512768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.